This approval was based on results from the TRITON-TIMI 38 clinical trial which compared Effient with Plavix (clopidogrel bisulfate tablets, from Bristol-Myers Squibb and Sanofi-Aventis) in reducing cardiovascular events in 13,608 acute coronary patients managed with PCI.